02 April 2019 : Clinical Research
Impact of Insurance Status on Stage, Treatment, and Survival in Patients with Colorectal Cancer: A Population-Based Analysis
Wei Sun1ABCD, Minghua Cheng1BCDE, Shaohui Zhuang1CDE, Zeting Qiu1ABEF*DOI: 10.12659/MSM.913282
Med Sci Monit 2019; 25:2397-2418
Abstract
BACKGROUND: This study aimed to analyze data from the Surveillance, Epidemiology, and End Results (SEER) program to identify patients with colorectal cancer (CRC) who had specific insurance details and the effects of stage at diagnosis, definitive treatment, and survival outcome with insurance status.
MATERIAL AND METHODS: Between 2007 and 2009, SEER database analysis identified 54,232 patients with CRC. Logistic models examined the associations between insurance status and disease stage and definitive treatment. Kaplan-Meier analysis, the Cox model, and the Fine and Gray model were used to compare the tumor cause-specific survival (TCSS) for patients with different insurance status.
RESULTS: Insured patients were more likely to have earlier tumor stage at diagnosis when compared with patients receiving Medicaid (adjusted OR, 1.318; 95% CI, 1.249–1.391; P<0.001) and when compared with uninsured patients (adjusted OR, 1.479; 95% CI, 1.352–1.618; P<0.001). Insured patients were significantly more likely to undergo definitive treatment when compared with patients receiving Medicaid (adjusted OR, 0.591; 95% CI, 0.470–0.742; P<0.001) and compared with patients who were uninsured (adjusted OR, 0.404; 95% CI, 0.282–0.579; P<0.001). Insured patients had a significantly increased TCSS when compared with patients receiving Medicaid (HR, 1.298; 95% CI, 1.236–1.363; P<0.001) and compared with patients who were uninsured (HR 1.195, 95% CI, 1.100–1.297; P<0.001).
CONCLUSIONS: Insurance status was a significant factor that determined early diagnosis, definitive treatment, and clinical outcome and was an independent factor for TCSS in patients with CRC.
Keywords: Colorectal Neoplasms, Insurance Coverage, Survival Rate, Databases, Factual, Insurance, Health, Medicaid, Medically Uninsured, Proportional Hazards Models, SEER Program, United States
Editorial
01 February 2025 : Editorial
Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-SmokersDOI: 10.12659/MSM.948255
Med Sci Monit 2025; 31:e948255
In Press
Clinical Research
Pre- and Post-Surgical MRI Analysis of Levator Ani in Pelvic Organ Prolapse Patients: A Single-Center StudyMed Sci Monit In Press; DOI: 10.12659/MSM.945993
Clinical Research
Comparative Impact of Kinesio Taping and Post-Isometric Muscle Relaxation on Pain and Myofascial Mechanics ...Med Sci Monit In Press; DOI: 10.12659/MSM.945376
Clinical Research
Surgical Efficacy in Varicocele Ligation with Ephedrine-Assisted Blood Pressure ControlMed Sci Monit In Press; DOI: 10.12659/MSM.946234
Clinical Research
Retrospective Study to Compare Injury Patterns and Associations in 170 Patients Following Electric Scooter ...Med Sci Monit In Press; DOI: 10.12659/MSM.947155
Most Viewed Current Articles
17 Jan 2024 : Review article 6,968,277
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 701,791
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 25,442
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 20,020
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912